$8.20
0.49%
Nasdaq, Aug 29, 10:26 pm CET
ISIN
IE00B91XRN20
Symbol
PRTA

Prothena Corp. Plc Stock price

$8.20
+1.27 18.33% 1M
-7.61 48.13% 6M
-5.65 40.79% YTD
-13.36 61.97% 1Y
-20.10 71.02% 3Y
-4.76 36.73% 5Y
-49.33 85.75% 10Y
+1.00 13.89% 20Y
Nasdaq, Closing price Fri, Aug 29 2025
-0.04 0.49%
ISIN
IE00B91XRN20
Symbol
PRTA
Industry

Key metrics

Basic
Market capitalization
$441.4m
Enterprise Value
$70.0m
Net debt
positive
Cash
$371.4m
Shares outstanding
53.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
42.7 | 17.1
EV/Sales
6.8 | 2.7
EV/FCF
negative
P/B
1.4
Financial Health
Equity Ratio
89.0%
Return on Equity
-25.1%
ROCE
-75.2%
ROIC
1,379.8%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$10.3m | $25.9m
EBITDA
$-248.1m | $0.0
EBIT
$-249.0m | $-216.7m
Net Income
$-302.9m | $-221.3m
Free Cash Flow
$-192.8m
Growth (TTM | estimate)
Revenue
-95.2% | -80.9%
EBITDA
-174.5% | 100.0%
EBIT
-172.5% | -40.2%
Net Income
-494.8% | -80.9%
Free Cash Flow
-91.2%
Margin (TTM | estimate)
Gross
-
EBITDA
-2,399.2% | 0.0%
EBIT
-2,407.9%
Net
-2,929.3% | -855.9%
Free Cash Flow
-1,864.8%
More
EPS
$-5.6
FCF per Share
$-3.6
Short interest
14.6%
Employees
163
Rev per Employee
$830.0k
Show more

Is Prothena Corp. Plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Prothena Corp. Plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Prothena Corp. Plc forecast:

9x Buy
64%
4x Hold
29%
1x Sell
7%

Analyst Opinions

14 Analysts have issued a Prothena Corp. Plc forecast:

Buy
64%
Hold
29%
Sell
7%

Financial data from Prothena Corp. Plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
10 10
95% 95%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 67 67
0% 0%
649%
- Research and Development Expense 192 192
20% 20%
1,859%
-248 -248
174% 174%
-2,399%
- Depreciation and Amortization 0.90 0.90
7% 7%
9%
EBIT (Operating Income) EBIT -249 -249
173% 173%
-2,408%
Net Profit -303 -303
495% 495%
-2,930%

In millions USD.

Don't miss a Thing! We will send you all news about Prothena Corp. Plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Prothena Corp. Plc Stock News

Neutral
Business Wire
4 days ago
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference on Thursday, September...
Neutral
Business Wire
5 days ago
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program.
Neutral
Business Wire
26 days ago
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena announced that Novo Nordisk communicated that they expect to advance coramitug into a Phase 3 program for ATTR-CM in 2025.
More Prothena Corp. Plc News

Company Profile

Prothena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and development of novel therapies to change the course of devastating diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Head office Ireland
CEO Gene Kinney
Employees 163
Founded 1969
Website www.prothena.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today